Discovery of potential WEE1 inhibitors via hybrid virtual screening
Frontiers in Pharmacology · 07.12.2023 · 14
DOI: 10.3389/fphar.2023.1298245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.12.2023. Verfasst von Tingting Jin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacology, Affiliated Hangzhou…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
G 2 /M cell cycle checkpoint protein WEE1 kinase is a promising target for inhibiting tumor growth. Although various WEE1 inhibitors have entered clinical investigations, their therapeutic efficacy and safety profile remain unsatisfactory. In this study, we employed a comprehensive virtual screening workflow, which included Schrödinger-Glide molecular docking at different precision levels, as well as the utilization of tools such as MM/GBSA and Deepdock to predict the binding affinity between targets and ligands, in order to identify potential WEE1 inhibitors. Out of ten molecules screened, 50% of these molecules exhibited strong inhibitory activity against WEE1. Among them, compounds 4 and 5 showed excellent inhibitory activity with IC 50 values of 1.069 and 3.77 nM respectively, which was comparable to AZD1775. Further investigations revealed that compound 4 displayed significant anti-proliferative effects in A549, PC9, and HuH-7 cells and could also induce apoptosis and G1 phase arrest in PC9 cells. Additionally, molecular dynamics simulations unveiled the binding details of compound 4 with WEE1, notably the crucial hydrogen bond interactions formed with Cys379. In summary, this comprehensive virtual screening workflow, combined with in vitro testing and computational modeling, holds significant importance in the development of promising WEE1 inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang…
- College of Pharmaceutical Sciences, Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, Zhejiang University, Hangzhou, China.
- School of Electrical and Information Engineering, Institute of Bioinformatics and Medical Engineering, Jiangsu University of Technology, Changzhou, China.
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, China.
- Department of Hepatopancreatobiliary Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zitieren
APA
Jin, T., Xu, W., Chen, R., Shen, L., Gao, J., Xu, L., Chi, X., Lin, N., Zhou, L., Shen, Z., & Zhang, B. (2023). Discovery of potential WEE1 inhibitors via hybrid virtual screening. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1298245
Vancouver
Jin T, Xu W, Chen R, Shen L, Gao J, Xu L, et al. Discovery of potential WEE1 inhibitors via hybrid virtual screening. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1298245
BibTeX
@article{Jin2023,
author = {Jin, Tingting and Xu, Wei and Chen, Roufen and Shen, Liteng and Gao, Jian and Xu, Lei and Chi, Xinglong and Lin, Nengming and Zhou, Lixin and Shen, Zheyuan and Zhang, Bo},
title = {Discovery of potential WEE1 inhibitors via hybrid virtual screening},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1298245}
}
EUVIMED